- Home
- GLUE vs MMI Comparison
GLUE vs MMI Comparison
Compare GLUE & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLUE | MMI |
|---|---|---|
| Founded | 2019 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GLUE | MMI |
|---|---|---|
| Price | $24.92 | $27.03 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 2 |
| Target Price | $27.00 | ★ $29.00 |
| AVG Volume (30 Days) | ★ 2.4M | 452.5K |
| Earning Date | 11-06-2025 | 02-13-2026 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | $181,538,000.00 | ★ $751,284,000.00 |
| Revenue This Year | $84.02 | $11.94 |
| Revenue Next Year | N/A | $15.59 |
| P/E Ratio | $100.27 | ★ N/A |
| Revenue Growth | ★ 1112.27 | 20.74 |
| 52 Week Low | $3.50 | $26.87 |
| 52 Week High | $25.77 | $41.94 |
Technical Indicators
Market Signals| Indicator | GLUE | MMI |
|---|---|---|
| Relative Strength Index (RSI) | 70.77 | 38.03 |
| Support Level | $13.69 | $26.87 |
| Resistance Level | $25.77 | $28.32 |
| Average True Range (ATR) | 1.49 | 0.62 |
| MACD | 0.81 | -0.00 |
| Stochastic Oscillator | 86.63 | 3.32 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.